Key result
Salvia miltiorrhiza active components boost myocardial glycolysis and promote post-MI angiogenesis in mice.
Why the study?
It remains unclear whether the cardioprotective mechanism of Salvia miltiorrhiza's active components involves regulation of endothelial glycolysis to promote angiogenesis during myocardial infarction treatment.
An optimal proportion of active components from Salvia miltiorrhiza promotes angiogenesis and provides cardioprotection in myocardial infarction models by enhancing endothelial glycolysis via the AMPK/PFKFB3 pathway.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for Salvia miltiorrhiza components in MI; human trials needed before clinical consideration.
ETHNOPHARMACOLOGICAL RELEVANCE: Myocardial infarction (MI), a leading cause of morbidity and mortality, may be treated by enhancing glycolysis in myocardial microvascular endothelial cells to promote angiogenesis. Salvia miltiorrhiza provides cardioprotection by modulating energy metabolism and angiogenesis. While our previous research identified an optimal proportion (OP) of its active components for myocardial protection, it remains unclear whether this mechanism involves the regulation of endothelial glycolysis to promote angiogenesis. AIM OF THE STUDY: To clarify the therapeutic mechanism by which OP exerts cardioprotective effects by promoting angiogenesis through the upregulation of myocardial endothelial glycolysis. MATERIALS AND METHODS: In this study, oxygen-glucose deprivation (OGD)-treated H9c2 cells were used to detect glycolysis levels, and OGD-treated short hairpin (sh)-6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase3 (PFKFB3) human umbilical vein endothelial cells (HUVECs), and MI C57BL/6 mice were used to detect glycolysis and angiogenesis. RESULTS: The results demonstrated that OP could increase glycolysis levels through adenosine 5'-monophosphate-activated protein kinase (AMPK)/PFKFB3, and then activate hypoxia-inducible factor-1α (HIF-1α)/vascular endothelial growth factor (VEGF)/VEGF receptor 2 (VEGFR2) to promote angiogenesis, improve myocardial histopathological morphology, attenuate myocardial fibrosis, reduce levels of myocardial enzymes, enhance cardiac function, and ultimately exert myocardial protective effects in MI mice. CONCLUSION: OP can enhance myocardial glycolysis through AMPK/PFKFB3, and then activate HIF-1α/VEGF/VEGFR2 to promote angiogenesis and serve as a therapy for MI. The preliminary elucidation of the efficacy and therapeutic mechanism of OP in MI provides a methodological basis for the clinical application and drug development of Salvia miltiorrhiza.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied Myocardial infarction. Optimal proportion (OP) of active components from Salvia miltiorrhiza was evaluated on Glycolysis levels, angiogenesis, and cardiac function. An optimal proportion of active components from Salvia miltiorrhiza enhanced myocardial glycolysis through AMPK/PFKFB3 and activated HIF-1α/VEGF/VEGFR2 to promote angiogenesis in MI mice.
Synapse has enriched 10 related papers. Consider them for comparative context: